Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left ventricular hypertrophy: why does it happen?

Gerard M London1

  • 1Department of Nephrology and Dialysis, Manhes Hospital, Fleury Mérogis, France. glondon@club-internet.fr

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|November 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2023
Same author

A case-control study indicates that coagulation imbalance is associated with arteriosclerosis and markers of endothelial dysfunction in kidney failure.

Kidney international·2020
Same author

Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study.

Journal of hypertension·2020
Same author

Ethical challenges in nephrology: a call for action.

Nature reviews. Nephrology·2020
Same author

Arterial Stiffness Gradient, Systemic Reflection Coefficient, and Pulsatile Pressure Wave Transmission in Essential Hypertension.

Hypertension (Dallas, Tex. : 1979)·2019
Same author

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2019
Same journal

Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Beyond Diffusion and Convection: Is Adsorption the Third Dimension of Dialysis?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Pivotal Clinical Trials in C3 Glomerulopathy: answers and remaining uncertainties.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Urinary protein vs albumin for assessing kidney failure risk in chronic kidney disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
See all related articles

Patients with end-stage renal disease (ESRD) experience high rates of cardiovascular disease, particularly left ventricular hypertrophy (LVH). While anemia correction helps, other factors also contribute to LVH in ESRD patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • End-stage renal disease (ESRD) patients exhibit significantly higher cardiovascular disease (CVD) rates compared to the general population.
  • Left ventricular hypertrophy (LVH) is a prevalent condition among ESRD patients.
  • Declining hemoglobin levels are known to impact left ventricular mass index.

Purpose of the Study:

  • To examine the complex pathophysiological aspects of left ventricular hypertrophy (LVH) in patients with end-stage renal disease (ESRD).
  • To review the role of anemia and its partial correction with recombinant human erythropoietin (epoetin) in managing LVH and associated cardiovascular risks in ESRD.

Main Methods:

  • Literature review and analysis of pathophysiological mechanisms.
  • Examination of existing data on hemoglobin levels, anemia correction, and cardiovascular outcomes in ESRD.

Related Experiment Videos

  • Discussion of multifactorial influences on LVH in ESRD patients.

    • Main Results:

    • Partial correction of anemia with epoetin has demonstrated benefits in reducing left ventricular mass and improving cardiovascular outcomes.
    • LVH in ESRD is a multifactorial condition, with anemia being one significant, but not the sole, contributing factor.
    • Further research is needed to fully elucidate all contributing factors to LVH in ESRD.

    Conclusions:

    • While epoetin therapy is beneficial for managing anemia-related LVH in ESRD, it does not fully resolve the issue.
    • Understanding the complex interplay of factors contributing to LVH is crucial for comprehensive patient management.
    • Addressing the multifaceted nature of LVH in ESRD is essential for improving cardiovascular health in this population.